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Abstract
Background: The macrophage, one of the several key immune cell types, is believed to be involved in tumorigenesis.
However, the mechanism of macrophages promoting tumor progression is largely unknown.
Methods: The differentially secreted proteins of M1 and M2 macrophages were analyzed by mass spectrometry. We
performed GST pull-down assay for the identification of cell-membrane receptors that interact with chitinase 3-like
protein 1 (CHI3L1) protein. The mouse model was used to validate the function of CHI3L1 in cancer metastasis in vivo.
Protein phosphorylation and gene expression were performed to study the signaling pathway activation of cancer cells
after CHI3L1 treatment.
Results: M2 macrophage-secreted CHI3L1 promoted the metastasis of gastric and breast cancer cells in vitro and in vivo.
The CHI3L1 protein functioned by interacting with interleukin-13 receptor α2 chain (IL-13Rα2) molecules on the plasma
membranes of cancer cells. Activation of IL-13Rα2 by CHI3L1 triggered the activation of the mitogen-activated protein
kinase signaling pathway, leading to the upregulated expression of matrix metalloproteinase genes, which promoted
tumor metastasis. The results of this study indicated that the level of CHI3L1 protein in the sera of patients with gastric or
breast cancer was significantly elevated compared with those of healthy donors.
Conclusions: Our study revealed a novel aspect of macrophages with respect to cancer metastasis and showed that
CHI3L1 could be a marker of metastatic gastric and breast cancer in patients.
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Background
Cell migration is an essential process for the development
and maintenance of multicellular organisms and is defined
as the orchestrated movement of cells in a particular dir-
ection to a specific location [1]. To migrate, a cell must
modify its shape to be able to interact with the surround-
ing tissue structures. Therefore, the extracellular matrix
(ECM) serves as a substrate as well as a barrier for an ad-
vancing cell body [2]. Cell migration is an integrated, mul-
tistep process that contributes to tissue repair and
regeneration, orchestrates embryonic morphogenesis and
drives disease progression. During cell migration, the
moving cell first becomes polarized and elongated. A
pseudopod is then formed, which attaches to the ECM
substrate. Subsequently, regions of the leading edge con-
tract, thereby generating a traction force that leads to the
gradual forward gliding of the cell body and its trailing
edge. Metastasis, which involves the migration of cancer
cells from the primary tumor to a distant organ or tissue,
is the most frequent cause of death for patients with can-
cer. Cancer cells utilize cell migration mechanisms that
are similar to those exhibited by non-neoplastic cells dur-
ing physiological processes [2]. The steps of metastasis in-
clude tumor cell adhesion to and invasion of basement
membranes and the surrounding tissue, intravasation into
blood vessels, survival in the bloodstream, extravasation,
and growth at different organ sites [2]. Only a small pro-
portion of tumor cells invade and disseminate. However,
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the molecular mechanisms underlying metastasis are still
poorly understood because of their apparent complexity.
Tumor progression is controlled by crosstalk between
cancer cells and other cell types within the tumor micro-
environment. The tumor microenvironment includes pro-
liferating tumor cells, blood vessels, the tumor stroma,
inflammatory cells, and a variety of associated tissue-type
cells. This unique environment forms over the course of
tumor progression due to the interactions of tumor cells
with the host. This microenvironment is shaped and domi-
nated by the tumor, which orchestrates molecular and cel-
lular events occurring in the surrounding tissues. Although
various immune effector cells are recruited to the tumor
site, their anti-tumor functions are downregulated, largely
in response to tumor-derived signals. Immune effector cells
in the tumor microenvironment not only fail to perform
anti-tumor functions but are co-opted to promote tumor
growth [3]. Macrophages are a key component of the
tumor microenvironment that act as facilitators of tumor
cell migration and invasion, matrix degradation, and angio-
genesis. The density of macrophages in the tumor micro-
environment has been found to be a prognostic marker of
poor outcome for a variety of carcinomas. Evidence from
clinical and experimental studies has indicated that tumor-
associated macrophages (TAMs) promote solid-tumor
metastasis by releasing a variety of cytokines, including che-
mokines, inflammatory factors, and growth factors [4–6].
For example, macrophages can promote angiogenesis by se-
creting IL-1, VEGF, and MMP-2 [7]. Growth factors and
proteases produced by macrophages can initiate tumorigen-
esis and enhance tumor progression [8]. However, many
cytokines that are produced by cancer cells themselves also
contribute to carcinogenesis [9]. Elevated cytokine expres-
sion may be a diagnostic cancer marker. Currently, TAM
cytokine profiles are largely unknown. It is unclear whether
there are some exclusively TAM-derived cytokines that are
functionally essential to tumor progression.
There are different types of macrophages, such as M1
and M2 macrophages [10]. Phagocytosis mediated by
macrophages (M1 macrophages) is essential to the im-
mune response of animals, as revealed in our previous
studies [11–14]. M2 macrophages can suppress inflamma-
tory responses as well as promote angiogenesis and tissue
remodeling and repair [10]. Our previous studies indicated
that inhibition of microRNA-100 triggered apoptosis of
breast and cancer cells by inhibiting ubiquitination-
mediated p53 degradation [15, 16], revealing a vital role of
microRNAs in tumor progression. To further explore the
role of macrophages in tumor progression, the proteins
secreted by macrophages were characterized in this study.
The results indicated that M2 macrophages are recruited
by tumor cells. The M2-secreted chitinase 3-like protein 1
(CHI3L1) promoted the metastasis of gastric and breast
cancer cells by triggering the mitogen-activated protein
kinase (MAPK) signaling pathway. Therefore, our study
revealed a novel macrophage-mediated mechanism that
underlies cancer cell metastasis.
Methods
Identification of CHI3L1 secreted by M2 macrophages
M1 and M2 macrophages were cultured in serum-free
medium for 24 h. Then, the culture supernatants were
collected and were dialysed against 1 L of distilled water
overnight at 4 °C. The secreted proteins were resolved
on a 15% SDS-PAGE denaturing gel and were visualized
using Coomassie Brilliant Blue. The protein band of
interest was removed for mass spectrometry analysis.
Identification of cell-membrane receptors that interact
with CHI3L1 protein
GST (glutathione S transferase)-conjugated CHI3L1 pro-
tein was expressed in E. coli BL21 cells and was purified
using standard protocols. Glutathione-Sepharose beads
(GE Healthcare, Waukesha, WI, USA) coupled with either
GST or with the GST-CHI3L1 purified protein were incu-
bated with the solubilized membrane proteins for 1 h at
4 °C. The membrane proteins of the gastric and breast
cancer cells were extracted using a ProteoExtract Native
Membrane Protein Extraction kit (Calbiochem, San Diego,
CA, USA) according to the manufacturer’s instructions.
After rinsing the beads three times with washing buffer
(50 mM HEPES-KOH, 150 mM NaCl, 1 mM MgCl2, 0.2%
Triton-X-100, pH 7.2), the proteins bound to the beads
were separated using 10% SDS-PAGE and were visualized
using Coomassie Brilliant Blue R-250 staining. The differ-
entially apparent proteins were excised from the gel and
were identified using mass spectrometry.
Assessment of breast cancer metastasis in vivo
The breast cancer metastasis assay was conducted in mice.
All the experiments using animals were performed in ac-
cordance with a protocol approved by the Institutional
Animal Care and Use Committee (IACUC). Female nude
mice of between 5 and 6 weeks old were used in this
study. Breast cancer cells (i.e., 2 × 105 MDA-MB-231 cells
or 8 × 105 MDA-MB-435 cells) stably expressing the firefly
luciferase reporter were mixed with 100 μl of PBS, and the
mixture was intravenously injected into the mice. 3 days
later, either recombinant CHI3L1 protein (rCHI3L1) or
PBS (as the control) was injected into the mice via the tail
vain at a dosage of 100 μg/kg of body weight. rCHI3L1 or
PBS was injected twice a week over a 7-week (MDA-MB-
231) or 11-week period (MDA-MB-435). For in vivo
imaging, the mice were given the substrate D-luciferin by
intraperitoneal injection at a dosage of 150 mg/kg in PBS,
after which lung metastasis was quantified every 2 weeks
by bioluminescence imaging using an IVIS Spectrum Im-
aging System (Perkin Elmer). Bioluminescence analysis
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was performed using Living Image software version 4.5
(Perkin Elmer). The solid tumors of mouse lungs were
harvested at the end of the experimental period for further
evaluation.
Detection of CHI3L1 protein in the sera of healthy donors
and metastatic cancer patients
Serum samples were obtained from patients in The First
Affiliated Hospital of Bengbu Medical College, China. The
samples were collected with the informed consent of the
patients, and all related procedures were performed with
the approval of the internal review and ethics boards of
the indicated hospital. For the co-immunoprecipitation
assay, the sera were centrifuged at 12,000 × g and 4 °C for
10 min. Then, the supernatants were diluted in EBC lysis
buffer (50 mM Tris–HCl, 120 mM NaCl, and 2 mM
PMSF). To remove the antibodies from the sera, the su-
pernatants were incubated with Dynabeads® protein G
(Invitrogen) with gentle rotation at 4 °C for 2 h. After cen-
trifugation at 5,000 × g for 5 min, the supernatants were
incubated with the anti-CHI3L1 IgG-conjugated Dyna-
beads® protein G with gentle rotation at 4 °C overnight.
Subsequently, the mixture was washed twice using EBC
lysis buffer and was analyzed by western blotting using the
anti-CHI3L1 IgG.
Statistical analysis
All biological experiments were repeated three times inde-
pendently. Numerical data were analyzed using a one-way
analysis of variance. The statistical significance between
treatments was analyzed using Student’s t test.
Results
Tumor recruits M2 macrophages
To characterize the types of macrophages that participate
in tumorigenesis, solid tumors from patients with gastric
cancer were immunohistochemically analyzed by staining
for human leukocyte antigen-DRα (HLA-DRα, an M1
macrophage marker) and CD206 (an M2 macrophage
marker). The results showed that more CD206-positive
macrophages than HLA-DRα-positive macrophages were
present in the cancerous tissues (Fig. 1a, b). These findings
indicated that cancer cells recruited M2 macrophages
(i.e., tumor-associated macrophages) into the tumor
microenvironment.
Peripheral blood monocytes-derived M2 macrophages
promote cancer cell metastasis
To explore the effects of M2 macrophages on cancer cell
metastasis, THP-1 monocytes were polarized into M1
and M2 macrophages. After this polarization, the macro-
phages were co-cultured with tumor cells. Confocal mi-
croscopy demonstrated that monocytes could be
polarized into M1 or M2 macrophages (Fig. 2a). The
gene expression profiles that were determined revealed
that the expression levels of M1-associated genes (i.e.,
HLA-DRα, TNFα, IL-6, and iNOS) were significantly up-
regulated in M1 macrophages, whereas those of the M2-
associated genes, including CD204, CD206, CD301, and
Arginase-1, were significantly upregulated in M2 macro-
phages (Fig. 2b), indicating the successful polarization of
monocytes. The M2 macrophages were co-cultured with
gastric cancer cells (MKN-45, AGS, MGC-803, and
HGC-27), breast cancer cells (MDA-MB-231, MDA-
MB-435, and MDA-MB-468), or melanoma cells (A375).
The results of the Boyden chamber assays revealed that
the number of migrated MKN-45, AGS, MDA-MB-231,
MDA-MB-435, or MDA-MB-468 cells was significantly
increased when these cells were co-cultured with M2
macrophages (Fig. 2c and d), whereas co-culturing
MGC-803, HGC-27, or A375 cells with M2 macro-
phages did not affect the number of the cancer cells that
migrated compared with those observed in the treatment
medium-only group (Fig. 2c–e). However, co-culturing
M1 macrophages with cancer cells did not affect the
number of cancer cells that migrated (Fig. 2c–e),
Fig 1 Tumor recruits M2 macrophages. a Immunohistochemical staining of HLA-DRα (an M1 macrophage marker) and CD206 (an M2 macrophage
marker) in solid tumors from patients with gastric cancer. The tumor cells were stained with hematoxylin. The arrows indicate cancer cells, and the triangles
indicate macrophages. Scalebar, 20 μm. b Numbers of M1 and M2 macrophages in tumor tissues
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Fig 2 (See legend on next page.)
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suggesting that M2 macrophages play an important role
in gastric and breast cancer cell metastasis. To assess
whether the effect of M2 macrophages on cancer cell
metastasis was due to M2 macrophage secretions, the
M2 macrophage culture supernatant was added to cul-
tured cancer cells. The results indicated that the M2
macrophage culture supernatant significantly promoted
the migration of gastric cancer cells (MKN-45 and AGS)
and breast cancer cells (MDA-MB-231, MDA-MB-435,
and MDA-MB-468) (Fig. 2c, d), suggesting that M2
macrophage-derived secretions stimulated the metastasis
of these cancer cells. MKN-45 or AGS cells exhibited a
stretched and elongated morphology after co-culturing
with M2 macrophages or with the M2 culture super-
natant, whereas co-cultures with this cell type or the
supernatant did not affect the morphology of MGC-803
and HGC-27 cells (Fig. 2f ). These results suggested that
the morphological changes of MKN-45 and AGS cells
facilitated cancer cell metastasis mediated by M2 macro-
phages or by the M2 culture supernatant.
To further explore the effects of macrophages derived
from human samples on cancer cell metastasis, the periph-
eral blood monocytes of healthy humans were induced to
differentiate into M1 and M2 macrophages using LPS and
IL-4, respectively. Then, the cancer cells were co-cultured
with isolated M1 or M2 macrophages. The results indi-
cated that co-culturing isolated M2 macrophages and
gastric cancer cells (MKN-45 and AGS) or breast cancer
cells (MDA-MB-231, MDA-MB-435, and MDA-MB-468)
led to a significant increase in the number of migrated
cancer cells compared with the control (i.e., medium
alone) (Fig. 2g). However, M1 cells had no effect on cancer
cell migration (Fig. 2g). The data showed that the
monocyte-derived M2 macrophages promoted the migra-
tion of gastric cancer cells and breast cancer cells.
To assess the effects of isolated M2 macrophages on can-
cer cell adhesion and invasion, M1 or M2 macrophages
were co-cultured with the cancer cells, and the co-cultures
were subjected to adhesion and invasion assays. MKN-45
or AGS gastric cancer cell adhesion was significantly en-
hanced by co-culturing with M2 but not M1 cells (Fig. 2h).
The results obtained using MDA-MB-231, MDA-MB-435,
and MDA-MB-468 breast cancer cells were similar to
those obtained using gastric cancer cells (Fig. 2h). The in-
vasion assays showed that co-culturing isolated M2 macro-
phages and gastric or breast cancer cells resulted in a
significant increase of cancer cell invasion, whereas isolated
M1 cells had no effect on cancer cell invasion (Fig. 2i).
Taken together, the above findings indicate that
monocyte-derived M2 macrophages promote the metas-
tasis of gastric and breast cancer cells.
M2 macrophage-secreted CHI3L1 mediates cancer cell
metastasis
To determine which proteins secreted by M2 macro-
phages promote cancer cell metastasis including cancer
cell migration, adhesion, and invasion, M1 and M2
macrophage culture supernatants were collected and
were resolved on an SDS-PAGE denaturing gel. The re-
sults showed that a specific protein band was present in
the M2 supernatant but not in the M1 supernatant
(Fig. 3a). Mass spectrometry identification showed that
this protein was chitinase 3-like protein 1 (CHI3L1, also
called YKL-40) (Fig. 3a). To explore the expression of
CHI3L1 in M2 macrophages, the peripheral blood
monocytes of healthy humans were induced to generate
M1 and M2 macrophages, followed by the detection of
CHI3L1 protein. Western blot data showed that the
CHI3L1 protein was significantly upregulated in the iso-
lated M2 macrophages and their culture supernatants
compared with the isolated M1 macrophages (Fig. 3b),
suggesting that the CHI3L1 protein might play import-
ant roles in promoting cancer cell metastasis.
Recombinant CHI3L1 (rCHI3L1) protein was added to
gastric cancer cell culture (MKN-45 and AGS), breast
cancer cell culture (MDA-MB-231, MDA-MB-435, and
(See figure on previous page.)
Fig 2 M2 macrophages promote cancer cell metastasis. a Confocal microscopy of immunostained macrophages. THP-1 monocytes were polarized into
M1 or M2 macrophages. Macrophages were labeled with anti-HLA-DRα or anti-CD206. The nuclei were counterstained with DAPI. Scalebar, 20 μm. b
Gene expression profiles of M1 and M2 macrophages. M1 and M2 macrophage gene expression levels were quantified using real-time PCR. The genes
are shown on the horizontal axis. c, d, e Cancer cell migration characterized using Boyden chamber assays. Gastric cancer cells (MKN-45, AGS, MGC-803,
and HGC-27), breast cancer cells (MDA-MB-231, MDA-MB-435, and MDA-MB-468), or melanoma cells (A375) were co-cultured with M1 macrophages
(M1), M2 macrophages (M2), or M2 culture supernatant. The culture medium alone (medium) was included in the co-culture study as the control. After
12 h of co-culture, cell migration was evaluated. Scalebar, 100 μm. f The effect of co-culture on gastric cancer cell morphology. MKN-45, AGS, MGC-803,
or HGC-27 gastric cancer cells were co-cultured with culture medium (medium), M1 macrophages (M1), M2 macrophages (M2), or M2 culture
supernatant. 24 h later, the cancer cells were examined by phase-contrast microscopy. Scalebar, 50 μm. g Effects of peripheral blood monocytes-derived
M2 macrophages on gastric and breast cancer cell migration. The peripheral blood monocytes of healthy humans were induced to differentiate into
M1 macrophages using LPS or into M2 macrophages using IL-4. Isolated M1 and M2 cells were then co-cultured with cancer cells. Cancer cell migration
was examined using a Boyden chamber assay. Scalebar, 100 μm. h The role of peripheral blood monocytes-derived M2 macrophages in gastric and
breast cancer cell adhesion. Cancer cells were co-cultured with the isolated M1 or M2 macrophages and subjected to Boyden chamber assays. Scalebar,
100 μm. i The influence of peripheral blood monocytes-derived M2 macrophages on gastric and breast cancer cell invasion. Gastric or breast cancer cells
were co-cultured with isolated M1 or M2 cells, and then the cancer cells were analyzed using the invasion assay. Scalebar, 100 μm. In all the panels, the
significant differences are indicated by asterisks (*p < 0.05, **p < 0.01)
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MDA-MB-468), or melanoma cell culture (A375) for cell
migration assays using Boyden chambers. The results
showed that the migration of gastric or breast cancer
cells was significantly enhanced by the recombinant
CHI3L1 protein in a dose-dependent manner, whereas
CHI3L1 protein had no effect on the migration of A375
melanoma cells compared with the controls (Fig. 3c). To
explore the role of CHI3L1 in cancer cell invasion and
adhesion, gastric cancer cells (MKN-45 and AGS) or
breast cancer cells (MDA-MB-231, MDA-MB-435, and
MDA-MB-468) were cultured in media containing the
recombinant CHI3L1 protein and were subsequently
subjected to invasion and adhesion assays. The results
showed that gastric and breast cancer cell adhesion to fi-
bronectin was significantly increased by treatment with
CHI3L1 protein (Fig. 3d), indicating that CHI3L1 played
a positive role in cancer cell adhesion. Moreover,
CHI3L1 protein was shown to significantly enhance the
invasiveness of MKN-45, AGS, MDA-MB-231, MDA-
MB-435, and MDA-MB-468 cells compared with the
controls (Fig. 3e).
To confirm the effects of M2 cells-secreted CHI3L1
protein on cancer cell metastasis (cell migration, adhe-
sion and invasion), a polyclonal anti-CHI3L1 antibody
was added to the co-cultures of cancer cells and healthy
human peripheral blood monocytes-derived M2 macro-
phages to neutralize the activity of CHI3L1. The findings
revealed that the addition of anti-CHI3L1 led to a sig-
nificant decrease of gastric and breast cancer cell migra-
tion in the presence of isolated M2 macrophages
compared with the controls (Fig. 3f ), indicating that
CHI3L1 played a key role in cancer cell migration. To
neutralize the effect of CHI3L1 on gastric and breast
cancer cell adhesion, anti-CHI3L1 was added to the cell
cultures. In the presence of isolated M2 macrophages,
the number of adherent cancer cells was significantly re-
duced by the antibody compared with the controls
(Fig. 3g), showing that CHI3L1 appeared to be required
for cancer cell adhesion. When the antibody directed
against CHI3L1 (anti-CH3L1) was present in co-cultures
of isolated M2 cells and gastric or breast cancer cells,
the number of invaded cancer cells was significantly de-
creased compared with that of untreated co-cultures of
isolated M2 cells and cancer cells (Fig. 3h). These find-
ings revealed that monocyte-derived M2 macrophages
promoted the metastasis of gastric and breast cancer
cells via the CHI3L1 protein.
To explore the effects of silencing CHI3L1 gene ex-
pression on cancer cell metastasis, the expression level
of the CHI3L1 gene was knocked down using CHI3L1-
(See figure on previous page.)
Fig 3 M2 macrophage-secreted CHI3L1 mediates cancer cell metastasis. a Screening for different proteins secreted by M1 and M2 macrophages. The
secreted proteins were separated using SDS-PAGE and were stained with Coomassie Blue, after which they were identified by mass spectrometry. The
arrow indicates the protein identified using mass spectrometry. b The expression of CHI3L1 in M2 macrophages derived from the peripheral blood
monocytes of healthy humans. The peripheral blood monocytes were induced to differentiate into M1 and M2 macrophages. Then monocyte-derived M1
and M2 macrophages or their culture supernatants were subjected to western blotting analysis using anti-CHI3L1 IgG. c Effect of recombinant CHI3L1
protein on gastric and breast cancer cell migration in Boyden chamber assays. Gastric cancer cells (MKN-45 and AGS), breast cancer cells (MDA-MB-231,
MDA-MB-435, and MDA-MB-468), or melanoma cells (A375) were cultured with the recombinant CHI3L1 protein at different concentrations. 12 h later, the
cancer cells were examined by phase-contrast microscopy. Scalebar, 100 μm. d Roles of recombinant CHI3L1 protein in gastric and breast cancer cell
adhesion. Gastric cancer cells (MKN-45 and AGS) or breast cancer cells (MDA-MB-231, MDA-MB-435, and MDA-MB-468) were suspended in serum-free
medium and were allowed to adhere to a culture plate coated with fibronectin in the presence of recombinant CHI3L1 protein. After 30 min of incubation,
the cells were analyzed using the adhesion assay. Scalebar, 100 μm. e Effects of recombinant CHI3L1 protein on gastric and breast cancer cell invasion. The
invasive capacities of gastric cancer cells (MKN-45 and AGS) or breast cancer cells (MDA-MB-231, MDA-MB-435, and MDA-MB-468) in the presence of the
CHI3L1 protein were assessed. The cells were examined after 24 h of treatment. Scalebar, 100 μm. f The effects of anti-CHI3L1 neutralization on gastric or
breast cancer cell migration in Boyden chamber assays. Gastric cancer cells (MKN-45 and AGS) or breast cancer cells (MDA-MB-231, MDA-MB-435, and
MDA-MB-468) were co-cultured with the peripheral blood monocytes-derived M2 macrophages of healthy humans in the presence or absence of anti-
CHI3L1 antibody; IgG was used as the control. 12 h later, the cancer cells were examined by phase-contrast microscopy. Scalebar, 100 μm. g The influence
of neutralizing CHI3L1 protein on gastric or breast cancer cell adhesion. The adhesion capacity of cancer cells in the presence of the peripheral blood
monocytes-derived M2 macrophages and anti-CHI3L1 was evaluated. Scalebar, 100 μm. h Evaluation of the role of anti-CHI3L1 neutralization in gastric or
breast cancer cell invasion. Cancer cells and isolated M2 macrophages were co-cultured and were then subjected to the invasion assay in the presence or
absence of the anti-CHI3L1 antibody. Scalebar, 100 μm. i CHI3L1 gene expression silencing in isolated M2 macrophages from the peripheral blood
monocytes of healthy humans. Isolated M2 macrophages were transfected with CHI3L1-siRNA or CHI3L1-siRNA-scrambled. At 24 h after transfection, the
CHI3L1 protein level was determined using western blotting. β-actin served as a loading control. j Effects of CHI3L1 silencing in isolated M2 macrophages
on gastric and breast cancer cell migration. The CHI3L1-silenced isolated M2 macrophages were co-cultured with cancer cells and subjected to cell
migration assays. Scalebar, 100 μm. k The impact of CHI3L1 silencing on gastric and breast cancer cell adhesion. The CHI3L1 gene expression was knocked
down in the isolated M2 macrophages. 24 h later, the M2 macrophages were co-cultured with cancer cells, and the adhesion capacities of cancer cells
were examined. Scalebar, 100 μm. l The influence of CHI3L1 silencing on gastric and breast cancer cell invasion. Cancer cells were co-cultured with the
CHI3L1-silenced isolated M2 macrophages and then cell invasion assays were conducted. Scalebar, 100 μm. m Immunohistochemical staining of CHI3L1
protein (up) and immunofluorescent double staining of CD206 (green) and CHI3L1 (red) (down) in solid tumors and pericarcinous tissues from patients
with gastric cancer. In immunohistochemical staining, the arrows indicate cancer cells, and the triangles indicate CHI3L1 protein. Scalebar, 20 μm. In
immunofluorescent double staining, the arrows show double-positive macrophages. Scalebar, 10 μm. In all the panels, the significant differences are
indicated by asterisks (*p < 0.05, **p < 0.01)
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Fig 4 The mechanism underlying the CHI3L1-activated metastasis of gastric and breast cancer cells. a Identification of IL-13Rα2 as a CHI3L1-binding
membrane receptor. Glutathione-Sepharose beads coupled with GST or GST-CHI3L1 were incubated with isolated gastric and breast cancer cell membrane
proteins. The proteins bound to CHI3L1 protein were analyzed by 10% SDS-PAGE with Coomassie staining and were identified by mass spectroscopy. b
Interaction between CHI3L1 and IL-13Rα2. Gastric and breast cancer cells were incubated with recombinant CHI3L1 (rCHI3L1) for 3 h. Then, the cell
membrane proteins were prepared for analysis of the levels of CHI3L1 and IL-13Rα2 using western blot assays (top). Additionally, the cell membrane
proteins were immunoprecipitated (IP) using either anti-CHI3L1 or an isotype IgG antibody and were analyzed by western blotting (bottom). Cells not
treated with rCHI3L1 were used as controls. c Co-localization of CHI3L1 and IL-13Rα2 proteins on the plasma membrane of cancer cells. MDA-MB-231 cells
were incubated with rCHI3L1 for 3 h. Subsequently, the cells were stained with fluorescently labeled anti-CHI3L1 and anti-IL-13Rα2. The nuclei were
counterstained with DAPI. The cells were examined using confocal microscopy. d Effect of CHI3L1-mediated IL-13Rα2 activation on triggering the activity
of the MAPK and PI3K/AKT signaling pathways. Gastric and breast cancer cells with or without IL-13Rα2-siRNA transfection were incubated with rCHI3L1
protein for 3 h. Western blot analysis was conducted to evaluate the levels of total and phosphorylated ERK, JNK, Src, and AKT proteins. β-actin was used
as the control. e Effects of CHI3L1-mediated IL-13Rα2 activation on AP-1 transcriptional activity in cancer cells. Cancer cells with or without IL-13Rα2-siRNA
transfection were transfected with plasmids containing the binding sequence of the AP-1 transcription factor family. Then, recombinant CHI3L1 protein
(rCHI3L1) was added to the cell cultures. Dual-luciferase reporter assays were conducted. The level of AP-1 transcriptional activity of the cancer cells was
normalized to that of the untreated cells. f Influence of CHI3L1-IL-13Rα2 interaction on c-Fos and c-Jun protein expression in the nuclei of cancer cells.
Gastric and breast cancer cells with or without IL-13Rα2-siRNA transfection were treated with rCHI3L1 at 10 nM for 3 h. Then, the levels of c-Fos and c-Jun
proteins in the cancer cell nuclei were determined by western blotting. g Evaluation of MMP expression. Cancer cells with or without IL-13Rα2-siRNA
transfection were incubated with rCHI3L1 at 10 nM for 3 h. Subsequently, the cells were subjected to quantitative real-time PCR to determine the levels of
MMP expression. h, i Effects of ERK inhibitor (U0126) and JNK inhibitor (SP600125) on the CHI3L1-induced aggregation of c-Fos and c-Jun protein in the
nuclei h and MMP gene expression i in MKN-45 cells (left) and MDA-MB-231 cells (right). Prior to the addition of recombinant CHI3L1 protein, cancer cells
were treated with U0126 or/and SP600125 at 10 μM for 2 h. Then the cancer cells were incubated with rCHI3L1 protein for 3 h. Significant differences
between the treatments are indicated by asterisks (*p< 0.05, **p< 0.01)
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siRNA in isolated M2 macrophages compared with the
control level (Fig. 3i). The results showed that silencing
CHI3L1 expression in isolated M2 cells led to significant
decreases of cancer cell migration, adhesion, and invasion
compared with the control levels (Fig. 3j–l). These find-
ings indicated that CHI3L1 was required for gastric and
breast cancer cell metastasis.
To determine the distribution of CHI3L1 protein in
cancer tissues, an immunohistochemistry analysis using
anti-CHI3L1 and an immunofluorescent double staining
using anti-CHI3L1 and anti-CD206 were conducted. The
results showed that CHI3L1 protein was localized in the
stroma of gastric carcinomas (Fig. 3m). However, no posi-
tive signal was observed in the pericarcinous tissue
(Fig. 3m). These findings suggested that CHI3L1 protein
plays an important role in cancer progression.
Collectively, the data described above indicated that
M2 macrophages promote gastric and breast cancer cell
metastasis (cell migration, adhesion, and invasion) via
the M2 macrophage-secreted CHI3L1 protein.
The mechanism underlying CHI3L1-activated gastric and
breast cancer cell metastasis
To reveal the mechanism underlying CHI3L1-activated
gastric and breast cancer cell metastasis, cancer cell mem-
brane receptors were screened using GST pull-down as-
says with recombinant GST-CHI3L1 protein. A specific
protein band was observed in the resulting pull-down
product (Fig. 4a). Mass spectrometry was used to identify
the protein band as interleukin (IL)-13 receptor α2 chain
(IL-13Rα2). When cancer cells were incubated with the re-
combinant CHI3L1 protein (rCHI3L1), the CHI3L1 pro-
tein bound IL-13Rα2 (Fig. 4b, bottom panel), indicating an
interaction between the two proteins. Moreover, the data
revealed that CHI3L1 protein had no effect on IL-13Rα2
expression (Fig. 4b, top panel). Confocal microscopy ana-
lysis demonstrated that CHI3L1 protein was co-localized
with IL-13Rα2 on the plasma membrane of cancer cells
(Fig. 4c). These data indicated that CHI3L1 protein could
interact with the IL-13Rα2 receptors on the plasma mem-
brane of MKN-45 and AGS gastric cancer cells and MDA-
MB-231, MDA-MB-435, and MDA-MB-468 breast cancer
cells. However, the CHI3L1-IL-13Rα2 interaction was not
observed in MGC-803 and HGC-27 gastric cancer cells or
A375 melanoma cells due to the lack of IL-13Rα2 on their
plasma membranes (data not shown). This phenomenon
was consistent with the CHI3L1-activated cancer cell me-
tastasis described above (Figs. 2 and 3). In this context,
these findings showed that CHI3L1 promoted cancer cell
metastasis by interacting with IL-13Rα2 on cancer cell
membranes.
Previous studies have revealed that the activation of
IL-13Rα2 by IL-13 triggers the MAPK signaling pathway
by phosphorylating extracellular signal-regulated kinase
(ERK) 1/2 and c-Jun N-terminal kinase (JNK) in pancreatic
and ovarian cancers and the phosphoinositide 3-kinase
(PI3K)/AKT pathway by phosphorylating Src and AKT in
colorectal cancer [17–19]. As shown in Fig. 4d, adding
CHI3L1 protein to gastric cancer cell (MKN-45 and AGS)
and breast cancer cell (MDA-MB-231, MDA-MB-435, and
MDA-MB-468) cultures promoted the phosphorylation of
ERK and JNK but not Src and AKT, which was abolished
by IL-13Rα2 gene silencing in cancer cells. These results in-
dicated that the activation of IL-13Rα2 by CHI3L1 trig-
gered only the MAPK signaling pathway in gastric and
breast cancers.
In the MAPK signaling pathway, the phosphorylation of
ERK 1/2 and JNK activates the AP (activator protein)-1
transcription factor family, including c-Fos and c-Jun, and
thus promotes the expression of matrix metalloproteinases
(MMPs) in cancer cells [19–21]. The luciferase reporter as-
says showed that AP-1 transcriptional activity in cancer
cells was significantly increased by the addition of rCHI3L1
protein compared with the control (Fig. 4e), indicating that
AP-1 transcriptional activity was activated by CHI3L1 pro-
tein. Western blots showed that the presence of CHI3L1
dramatically elevated the levels of c-Fos and c-Jun proteins
in cancer cell nuclei (Fig. 4f), confirming the activation of
the AP-1 family by CHI3L1. Further data indicated that the
activation of the AP-1 family by CHI3L1 significantly up-
regulated the levels of MMP expression in cancer cells
(Fig. 4g). However, different MMPs were upregulated by
CHI3L1 in different cancer cell types. The results showed
that knockdown of IL-13Rα2 gene expression in cancer
cells significantly reduced the CHI3L1-induced activation
of AP-1 transcription factors and upregulation of MMP
gene expression in cancer cells (Fig. 4e–g).
To further explore the role of CHI3L1 protein in
the CHI3L1-AP-1-MMP pathway, cancer cells were
treated with ERK inhibitor (U0126) or JNK inhibitor
(SP600125), followed by the addition of CHI3L1 pro-
tein in MKN-45 and MDA-MB-231 cells. The data
presented that ERK inhibitor or/and JNK inhibitor re-
sulted in decreased aggregation of c-Fos and c-Jun
proteins in the nuclei of cancer cells compared with
the control (Fig. 4h). At the same time, CHI3L1-
induced upregulation of MMP genes in MKN-45 and
MDA-MB-231 cancer cells was eliminated when
treated with inhibitors (Fig. 4i).
Taken together, these findings demonstrated that the
IL-13Rα2 receptor activated the MAPK signaling path-
way following CHI3L1 stimulation, thus promoting can-
cer cell metastasis.
CHI3L1-mediated promotion of in vivo breast cancer lung
metastasis
To investigate the effect of CHI3L1 on breast cancer me-
tastasis in vivo, MDA-MB-231 or MDA-MB-435 cells with
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a stably integrated luciferase reporter were intravenously
injected into nude mice. These mice were then evaluated
for cancer metastasis to the lungs (Fig. 5a). The quantita-
tive bioluminescence imaging analysis showed that the
metastasis of MDA-MB-231 cells to the lung could be de-
tected 1 week after the injection, whereas MDA-MB-435
cell metastasis was detected 3 weeks after the injection
(Fig. 5b). The mice injected with the CHI3L1 protein ex-
hibited much higher lung metastasis luciferase signals than
the control (i.e., mice injected with only PBS) (Fig. 5b, c),
indicating that CHI3L1 protein promoted cancer metasta-
sis in vivo.
To evaluate whether in vivo cancer metastasis resulted
from the activation of the MAPK signaling pathway by the
CHI3L1-IL-13Rα2 interaction, the MAPK pathway in the
metastatic tumors of mouse lungs was examined. All the
mice treated with rCHI3L1 presented remarkably in-
creased levels of phosphorylation of ERK and JNK but not
Src and AKT compared with the controls (i.e., mice
treated with PBS alone) (Fig. 5d); these results corre-
sponded with those obtained using the cancer cell lines
(Fig. 4f). Additionally, the c-Fos and c-Jun expression
levels in the nuclei of metastatic tumors of mouse lungs
were significantly upregulated in response to rCHI3L1
Fig 5 CHI3L1-mediated promotion of in vivo breast cancer lung metastasis. a Schematic diagram of cancer cell metastasis to the lung following
intravenous injection. b Effects of CHI3L1 protein on in vivo breast cancer cell metastasis. MDA-MB-231 and MDA-MB-435 breast cancer cells were
intravenously injected into nude mice (n = 5/treatment). 3 days later, recombinant CHI3L1 protein was injected into the mice; PBS alone was used
as the control. Lung metastasis was monitored via in vivo quantitative luciferase bioluminescence imaging every 2 weeks. The numbers on
the horizontal axis indicate the weeks after the injection of CHI3L1 protein. c Representative images of MDA-MB-231 cell metastasis (week 7)
and MDA-MB-435 cell metastasis (week 11) in mice. d Western blotting-based determination of the levels of phosphorylation of ERK, JNK, Src,
and AKT proteins in metastatic mouse tumors. The solid tumors separated from mouse lungs were used for this analysis. The treatments are shown at
the top. The numbers indicate the number of mice used. β-actin served as the loading control. e Levels of c-Fos and c-Jun expression in the nuclei of
the metastatic tumor cells of mice treated with CHI3L1 protein or PBS. Western blot analysis was conducted using the solid tumors from mouse lungs.
The numbers indicate the number of mice used. f MMP gene expression profiles in metastatic mouse tumors. Metastatic mouse tumors treated with
CHI3L1 protein or PBS were subjected to quantitative real-time PCR to quantify the gene expression levels. The columns show the data for five mice.
Significant differences between the mice treated with CHI3L1 protein and PBS are represented by asterisks (**p < 0.01). g Schematic diagram of the
signaling cascades activated by CHI3L1 treatment of cancer cells
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treatment (Fig. 5e); these results were also consistent with
those obtained using the cancer cell lines (Fig. 4h). The
MMP gene expression profiles in the metastatic tumors of
all the mice treated with rCHI3L1 (Fig. 5f) were similar to
those of the cancer cell lines (Fig. 4i). Based on the data
obtained in our study, a diagram of the signaling cascades
involved in CHI3L1-induced cancer cell metastasis was
constructed and is shown in Fig. 5g.
Collectively, these data indicated that CHI3L1 protein
promoted in vivo breast cancer metastasis by activating the
IL-13Rα2 receptor and subsequently, the MAPK pathway.
High levels of CHI3L1 protein in the sera of patients with
gastric or breast cancer
To assess whether CHI3L1 protein secreted into the sera
of patients with cancer, the levels of CHI3L1 in the sera of
healthy donors and metastatic cancer patients were deter-
mined. Western blots showed that CHI3L1 protein was
present in the sera of gastric and breast cancer patients but
not in the sera of healthy donors (Fig. 6a). These data indi-
cated that because CHI3L1 protein could be detected in
serum samples, this protein could serve as a marker of
metastatic gastric and breast cancer.
Based on examination of the Oncomine and the Gene
Expression Omnibus (GEO) databases, high levels of
CHI3L1 expression in human tissues correlated with the
progression of both gastric cancer (Fig. 6b) and breast
cancer (Fig. 6c). These collective data suggested a signifi-
cant correlation between increased CHI3L1 expression
and primary human tumorigenic progression.
Discussion
Metastasis represents a continuum that begins with can-
cer cell invasion through the basement membrane into
the surrounding stroma, which is followed by extravasa-
tion into the circulatory system and the establishment of
neoplastic cell colonies at distant sites [22]. There is in-
creasing evidence that macrophages play important roles
in modulating the tumor metastatic capacity [23]. Macro-
phages originate from blood monocytes and differentiate
into distinct macrophage types, which are typically identi-
fied as M1 (classically activated) and M2 (alternatively
activated) macrophages. M1 macrophages are efficient im-
mune effector cells that kill invading microorganisms and
tumor cells, present antigens and produce high levels of
T-cell stimulatory cytokines. M2 macrophages, however,
have poor antigen-presenting capabilities [24]. These cells
produce factors that suppress T-cell proliferation and ac-
tivity and are generally better adapted to promoting angio-
genesis and tissue remodeling and repair. Increasing
amounts of data have shown that tumor-associated mac-
rophages (TAMs) are polarized M2 macrophages [24].
Genetic studies in mice have indicated that decreased
numbers of macrophages in tumors are associated with
notably reduced cancer metastasis rates [25]. Although it
is known that cytokines secreted by TAMs facilitate can-
cer cell migration, few TAM cytokines have been investi-
gated. It has been reported that the levels of TAM-derived
tumor growth factor-β1 (TGF-β1), epidermal growth fac-
tor (EGF), chemokine [C-C motif] ligand 18 (CCL18),
interleukin (IL)-18, IL-1β, and IL-8 are correlated with
tumor progression [6, 26–30]. Paracrine loops of colony-
Fig 6 High levels of CHI3L1 protein in the sera of patients with cancer. a Detection of CHI3L1 protein in sera. The CHI3L1 protein in the sera of healthy
donors and metastatic gastric or breast cancer patients (n= 5/group) was immunoprecipitated using anti-CHI3L1. Then, the immunoprecipitated proteins
were subjected to western blot analysis using anti-CHI3L1. b CHI3L1 expression levels in gastric cancer tissues. CHI3L1 expression levels in the normal and
cancerous tissues of the same patients were analyzed using both the Oncomine and the Gene Expression Omnibus (GEO) databases. c CHI3L1 expression
levels in the normal and cancerous tissues of patients with breast cancer were also evaluated using the Oncomine and GEO databases
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stimulating factor-1 (CSF-1)/EGF and granulocyte-
macrophage colony-stimulating factor (GM-CSF)/CCL18
between carcinoma cells and macrophages have been
shown to lead to increased carcinoma cell invasion [31].
However, little is known about the role of the proteins se-
creted by TAMs in cancer metastasis. The results of this
study demonstrated that CHI3L1, which is secreted by
M2 macrophages, promoted cancer metastasis by activat-
ing the IL-13 receptors of cancer cells. Our study revealed
the existence of not only a novel M2-secreted oncogenic
protein (not a cytokine) but also a novel mechanism
underlying cancer metastasis.
CHI3L1, a glycoprotein, is highly expressed in human tu-
mors [32]. The administration of CHI3L1 has been shown
to promote endothelial cell migration and tube formation
in vitro but fails to protect cervical cancer cells against
apoptosis induced by γ-irradiation [33]. However, the effect
of M2 macrophage-derived CHI3L1 on cancer metastasis is
not previously addressed. The findings of this study re-
vealed that CHI3L1 specifically bound to the interleukin
(IL)-13 receptor α2 chain (IL-13Rα2) of gastric and breast
cancer cells, thus promoting cancer metastasis. These find-
ings were consistent with previously reported data [34]. As
a binding partner of IL-13Rα2, transmembrane protein 219
(TMEM219) plays a critical role in IL-13Rα2-mediated pul-
monary melanoma metastasis [35]. CHI3L1 stimulation
leads to TGF-β1 production during lung metastasis
[35]. In our study, the results showed that the activa-
tion of IL-13Rα2 triggered the downstream MAPK
signaling pathway through the phosphorylation of ERK 1/
2 and JNK. The phosphorylation of ERK1/2 and JNK led
to the recruitment of activator protein (AP)-1 family
members (transcription factors) in the nuclei [19, 21] and
thus promoted AP-1 target gene expression [36]. The
AP-1 target genes are a family of MMPs [19, 36–38].
In the stroma of invasive carcinomas, tumor cells produce
a variety of proteases, including various MMPs, to degrade
the basement membrane and the surrounding extracellu-
lar matrix (ECM), which leads to fibronectin being ex-
posed to the tumor cells [39]. Therefore, CHI3L1 could
promote the regional or distal metastasis of cancer. Our
data indicated that the CHI3L1 levels in the sera of pa-
tients with cancer were significantly elevated compared
with those of healthy donors, which suggests its potential
as a diagnostic marker of gastric and breast cancers.
Conclusions
In summary, these data showed that the M2-secreted
chitinase 3-like protein 1 (CHI3L1) could promote the
metastasis of gastric and breast cancer cells by triggering
the mitogen-activated protein kinase (MAPK) signaling
pathway. In this context, CHI3L1 has the potential to be
a therapeutic target for metastatic cancer. The clinical
diagnostic strategy of assessing serum CHI3L1 protein
levels merits future investigation.
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